Immunotherapy for cure and prophylaxis of allergic rhinitis

Y. Ohashi, Y. Nakai
{"title":"Immunotherapy for cure and prophylaxis of allergic rhinitis","authors":"Y. Ohashi,&nbsp;Y. Nakai","doi":"10.1111/j.1472-9733.2009.01142.x","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>The possible cure of Japanese cedar pollen-induced allergic rhinitis (AR) by immunotherapy was investigated. The mechanism of cure was also studied from the viewpoint of the T cell response to allergen; it was documented that absence of IL-5 production from allergen-stimulated T cells was the major mechanism. The prophylactic aspect of immunotherapy was also investigated. Eighty-eight asymptomatic subjects who were already sensitized to pollen were recruited. Of these subjects, 31 (prophylactic immunotherapy group) were treated with pollen immunotherapy for 3 years. The remaining 57 individuals (control group) were not treated with pollen immunotherapy. At the end of the 3-year trial, only 28 of 57 individuals (49.1%) in the control group remained asymptomatic. On the other hand, 27 of 31 individuals (87.1%) in the prophylactic immunotherapy group remained asymptomatic. Prophylactic immunotherapy decreased IL-4 synthesis from pollen allergen-stimulated T cells, suggesting that this was the mechanism of prevention of symptoms' outbreak. We next examined whether mite immunotherapy for patients monosensitized to mite allergen could prevent new sensitization to pollens. A total of 132 patients monosensitized to house dust mites were included. Of these individuals, 52 (pharmacotherapy group) were treated with antihistamine tablets for 4 years, and the remaining 80 patients (mite immunotherapy group) were treated with mite immunotherapy for the same time period. Whereas 15 of 52 patients (28.8%) in the pharmacotherapy group attained new sensitization to some kinds of pollen allergens, only five of 80 patients (6.3%) in the mite immunotherapy group attained new sensitization. Our data suggest that mite immunotherapy can prevent new sensitization to pollen allergens. It is therefore concluded that pollen immunotherapy cannot only cure pollen-induced AR but also prevent outbreaks of pollen-induced AR, and that mite immunotherapy can prevent new sensitization to pollen allergens.</p>\n </div>","PeriodicalId":100264,"journal":{"name":"Clinical & Experimental Allergy Reviews","volume":"9 1","pages":"6-10"},"PeriodicalIF":0.0000,"publicationDate":"2009-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1472-9733.2009.01142.x","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Experimental Allergy Reviews","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/j.1472-9733.2009.01142.x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

The possible cure of Japanese cedar pollen-induced allergic rhinitis (AR) by immunotherapy was investigated. The mechanism of cure was also studied from the viewpoint of the T cell response to allergen; it was documented that absence of IL-5 production from allergen-stimulated T cells was the major mechanism. The prophylactic aspect of immunotherapy was also investigated. Eighty-eight asymptomatic subjects who were already sensitized to pollen were recruited. Of these subjects, 31 (prophylactic immunotherapy group) were treated with pollen immunotherapy for 3 years. The remaining 57 individuals (control group) were not treated with pollen immunotherapy. At the end of the 3-year trial, only 28 of 57 individuals (49.1%) in the control group remained asymptomatic. On the other hand, 27 of 31 individuals (87.1%) in the prophylactic immunotherapy group remained asymptomatic. Prophylactic immunotherapy decreased IL-4 synthesis from pollen allergen-stimulated T cells, suggesting that this was the mechanism of prevention of symptoms' outbreak. We next examined whether mite immunotherapy for patients monosensitized to mite allergen could prevent new sensitization to pollens. A total of 132 patients monosensitized to house dust mites were included. Of these individuals, 52 (pharmacotherapy group) were treated with antihistamine tablets for 4 years, and the remaining 80 patients (mite immunotherapy group) were treated with mite immunotherapy for the same time period. Whereas 15 of 52 patients (28.8%) in the pharmacotherapy group attained new sensitization to some kinds of pollen allergens, only five of 80 patients (6.3%) in the mite immunotherapy group attained new sensitization. Our data suggest that mite immunotherapy can prevent new sensitization to pollen allergens. It is therefore concluded that pollen immunotherapy cannot only cure pollen-induced AR but also prevent outbreaks of pollen-induced AR, and that mite immunotherapy can prevent new sensitization to pollen allergens.

免疫疗法治疗和预防变应性鼻炎
探讨了免疫治疗杉木花粉致变应性鼻炎的可能性。并从T细胞对过敏原的应答角度探讨了其治疗机制;有文献表明,过敏原刺激的T细胞产生IL-5的缺失是主要机制。免疫治疗的预防方面也进行了研究。招募了88名已经对花粉敏感的无症状受试者。其中31例(预防性免疫治疗组)采用花粉免疫治疗3年。其余57例(对照组)未进行花粉免疫治疗。在3年的试验结束时,对照组中57名患者中只有28名(49.1%)没有症状。另一方面,预防性免疫治疗组31例患者中有27例(87.1%)仍无症状。预防性免疫治疗降低花粉过敏原刺激T细胞的IL-4合成,提示这是预防症状爆发的机制。接下来,我们研究了对螨过敏原单致敏的患者进行螨免疫治疗是否可以防止对花粉的新致敏。共纳入132例室内尘螨单敏感患者。其中52例(药物治疗组)使用抗组胺片治疗4年,其余80例(螨免疫治疗组)使用螨免疫治疗4年。药物治疗组52例患者中有15例(28.8%)对花粉过敏原产生新致敏,而螨免疫治疗组80例患者中仅有5例(6.3%)产生新致敏。我们的数据表明,螨免疫治疗可以防止对花粉过敏原的新致敏。因此,花粉免疫治疗不仅可以治愈花粉诱导的AR,还可以预防花粉诱导的AR的爆发,并且螨免疫治疗可以防止对花粉变应原的新致敏。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信